Q4 2022 Results slide image

Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology 2023 priorities Innovation: Clinical trials Ophthalmology Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 96 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation